Antibody Blocks C. Diff Recurrence

Recurrent Clostridium difficile disease (CDI) can be prevented by targeting one of its bacterial toxins with a monoclonal antibody, researchers reported here. In two Phase III randomized clinical trials, an antibody against the B toxin of C. difficile, combined with standard antibiotic care to cure acute CDI, reduced the risk of recurrence by about 50%. http://www.medpagetoday.com/MeetingCoverage/ICAAC/53666?xid=nl_mpt_DHE_2015-09-23&eun=g721819d0r